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Increased 15-PGDH expression 
leads to dysregulated resolution 
responses in stromal cells from 
patients with chronic tendinopathy
Stephanie G. Dakin1, Lucy Ly2, Romain A. Colas2, Udo Oppermann1,3, Kim Wheway1, Bridget 
Watkins1, Jesmond Dalli  2 & Andrew J. Carr1
The mechanisms underpinning the failure of inflammation to resolve in diseased musculoskeletal 
soft tissues are unknown. Herein, we studied bioactive lipid mediator (LM) profiles of tendon-derived 
stromal cells isolated from healthy donors and patients with chronic tendinopathy. Interleukin(IL)-1β 
treatment markedly induced prostaglandin biosynthesis in diseased compared to healthy tendon 
cells, and up regulated the formation of several pro-resolving mediators including 15-epi-LXA4 and 
MaR1. Incubation of IL-1β stimulated healthy tendon cells with 15-epi-LXA4 or MaR1 down-regulated 
PGE2 and PGD2 production. When these mediators were incubated with diseased cells, we only found 
a modest down regulation in prostanoid concentrations, whereas it led to significant decreases in 
IL-6 and Podoplanin expression. In diseased tendon cells, we also found increased 15-Prostaglandin 
Dehydrogenase (15-PGDH) expression as well as increased concentrations of both 15-epi-LXA4 
and MaR1 further metabolites, 15-oxo-LXA4 and 14-oxo-MaR1. Inhibition of 15-PGDH using either 
indomethacin or SW033291 significantly reduced the further conversion of 15-epi-LXA4 and MaR1 
and regulated expression of IL-6, PDPN and STAT-1. Taken together these results suggest that chronic 
inflammation in musculoskeletal soft tissues may result from dysregulated LM-SPM production, and 
that inhibition of 15-PGDH activity together with promoting resolution using SPM represents a novel 
therapeutic strategy to resolve chronic tendon inflammation.
Tendinopathy and other soft tissue diseases are a common global disease burden causing pain and prolonged 
disability, and an increasing component of health expenditure in ageing societies1, 2. Multiple therapies have been 
advocated to treat tendinopathy including physiotherapy, non-steroidal anti-inflammatory drugs (NSAIDs), and 
local injections of glucocorticoids. As disease progresses, tendons may tear or rupture3 causing considerable 
pain and incapacity, necessitating surgical repair, which is frequently associated with high post-operative failure 
rates4. There are currently no effective treatments for patients with non-resolving tendinopathy that address the 
underlying biology of disease.
The etiology of tendinopathy is multifactorial, encompassing effects of repetitive overuse, aging and genetic 
factors5, 6. Growing evidence supports the contribution of inflammation to the onset and progression of disease7–9, 
however the mechanisms underpinning development of chronic tendon inflammation are unknown. Whilst 
immune cells including macrophages and T cells are recognised contributors to the inflammatory process7, 9, 10, 
the relative contributions of tendon cells (resident stromal fibroblasts) to sustaining inflammation are under-
studied. We previously investigated inflammation activation pathways in cultured stromal cells derived from 
human tendons, demonstrating that stromal cells derived from patients with tendinopathy may be ‘primed’ for 
inflammation9. Tissues and cells derived from patients with tendinopathy show increased expression of markers 
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of stromal fibroblast activation including Podoplanin (PDPN), VCAM-1 (CD106) and Endosialin (CD248) com-
pared to healthy tendon tissues and cells11. Stromal fibroblast activation is a feature of Rheumatoid Arthritis (RA) 
in which resident stromal cells fail to switch off their inflammatory programme. These phenotypic alterations in 
RA synovial fibroblasts play an important role in the switch from resolving inflammation to persistent disease12, 13. 
Collectively, these studies support the concept that resident stromal fibroblasts are implicated in the persistence 
of chronic inflammation, although the mechanisms underpinning the failure of inflammation to resolve are not 
understood.
Inflammation resolution is an active and highly coordinated process whereby a repertoire of pro-resolving 
lipid mediators and proteins promote the timely resolution of inflammation after injury and/or infection14–16. 
Perturbed resolution is thought to contribute to the development of many systemic chronic inflammatory dis-
eases17, 18. Proresolving lipid mediators are well studied in experimental mouse models of systemic inflamma-
tion19, 20 as well as in humans21, 22. Evidence for their protective roles in chronic inflammatory diseases is growing, 
including periodontal disease23, inflammatory arthritis24 and pulmonary fibrosis25. Receptors implicated in medi-
ating the effects of proresolving lipid mediators including the lipoxin A4 receptor ALX/FPR2 and the Resolvin E1 
receptor ERV1/ChemR23 have been identified in diseased human tendons9, suggesting a role for these mediators 
in disease etiopathology. Of note, to date the presence of these pro-resolving mediators and their regulation in 
diseased human tendon cells remains of interest.
The present study focused on identification of mechanisms underpinning the development of chronic inflam-
mation in diseased human tendon tissues, which are currently poorly understood. We utilised an omics approach 
to perform a comprehensive analysis of pro-inflammatory and pro-resolving lipids in cultures of stromal fibro-
blasts derived from healthy and diseased human tendons. Using lipid mediator profiling, we identified differences 
in bioactive lipid mediator profiles between healthy and diseased tendon-derived stromal cells after treatment 
with IL-1β. We also investigated the biological actions of proresolving lipid mediators 15-epi-LXA4 and MaR1 on 
counter-regulating dysregulated resolution processes in diseased tendon cells. The findings from this study pro-
vide improved understanding of the biological roles of SPM in diseased musculoskeletal soft tissues. We identify 
a mechanism underpinning dysregulated resolution responses in stromal cells from patients with tendinopathy, 
and propose a novel therapeutic strategy to promote resolution of chronic tendon inflammation.
Results
Diseased tendon-derived stromal cells display dysregulated resolution responses. Lipid 
mediator (LM) profiling of healthy hamstring and diseased supraspinatus tendon-derived stromal cell cultures 
identified specialized pro-resolving lipid mediators (SPM) including D-series Resolvins (RvD1, RvD2, RvD3, 
RvD4, RvD5, RvD6, 17R-RvD1 and 17R-RvD3), Protectins (PD1, 17R-PD1), Maresins (MaR1), E-series Resolvins 
(RvE1, RvE2, RvE3), arachidonic acid-derived Lipoxins (LXA4, LXB4, 15-epi-LXA4 and 15-epi-LXB4) and n-3 
DPA-derived Resolvins RvD1n-3 DPA, RvD2n-3 DPA and RvD5n-3 DPA), Protectins (10 S,17S-diHDPA) and Maresins 
(MaR1n-3 DPA). These mediators were identified in accordance with published criteria that include matching reten-
tion times and at least 6 ions in the tandem mass spectrum26 (Fig. 1A,B, Supplementary Figure 1). Multivariate 
analysis uncovered differences in bioactive LM profiles between healthy and diseased tendon cells following incu-
bation with IL-1β (10ngml−1) for 24 hours as demonstrated by the distinct clustering of the LM profiles (Fig. 1A 
and B). Assessment of individual LM concentrations demonstrated significant increases in several SPM including 
Maresin (MaR) 1, n-3 DPA derived D-series resolvin (RvD1n-3 DPA), LXA4 and 15-epi-LXA4. In these incuba-
tions we also found significant increases in several inflammation initiating eicosanoids including PGE2 (Fig. 1C 
and Table 1). This increase in both SPM and eicosanoids in tendon derived stromal cells from patients with 
tendinopathy was coupled with a significant increase in the expression of several of their biosynthetic enzymes 
including ALOX12, ALOX15 and PTGS2 (Fig. 1D and E). These findings suggest that although SPM are up regu-
lated in stromal cells from patients with tendinopathy, their concentrations are not sufficient to counter regulate 
the ongoing inflammatory processes, reminiscent of a dysregulated resolution response characteristic of chronic 
inflammatory conditions27–29.
15-epi-LXA4 and MaR1 up regulate SPM production and reduce inflammatory responses in both 
diseased and healthy tendon-derived stromal cells. Having found altered LM-SPM profiles following 
addition of IL-1β, we next tested whether addition of 15-epi-LXA4 and MaR1, two of the mediators up regulated 
in diseased tendon stromal cell incubations (Fig. 1), modulated responses in stromal cells isolated from healthy 
hamstring and diseased supraspinatus tendons. Incubation of tendon-derived stromal cells with either 0.1 nM or 
10 nM 15-epi-LXA4 dose-dependently up regulated SPM production, including the DHA derived RvD, PD and 
MaR as well as the EPA derived E-series resolvins in healthy volunteer cell incubations (Fig. 2A, Supplemental 
Table 1). In addition, in these cell incubations we also found dose dependent decreases in the concentrations of 
inflammation initiating prostaglandins (PG), primarily PGE2, a mediator that carries both pro-inflammatory 
and nociceptive actions30 (Fig. 2B, Supplemental Fig. 2 and Supplemental Table 1). Of note, when 15-epi-LXA4 
was incubated with cells derived from patients with tendinopathy, these cells displayed blunted actions in up 
regulating SPM production (Fig. 2, Supplemental Fig. 2, Supplemental Table 2). We also found a dose dependent 
decrease in PG levels, however these decreases were less pronounced than those observed with cells from healthy 
volunteers. Moreover, 15-epi-LXA4 induced expression of ALOX15 mRNA relative to IL-1β-stimulated vehicle 
controls (Fig. 2C) and induced ALOX15 protein in diseased tendon stromal cells (n = 3 donors) (Fig. 2D).
We next assessed whether 15-epi-LXA4 also regulated other markers of tendon inflammation in 
patient-derived stromal cells. Incubation of IL-1β-stimulated diseased tendon cells with 10 nM 15-epi-LXA4 
reduced PDPN mRNA (p = 0.03) and protein, moderated STAT-1 mRNA and protein and reduced IL-6 mRNA 
and protein levels in tissue culture media (p = 0.002) (Fig. 2E–G).
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Figure 1. Distinct SPM profiles in IL-1β stimulated healthy and diseased tendon stromal cells. Tendon stromal 
cells (60,000 cells per well) were derived from healthy hamstring (n = 8 donors) or diseased supraspinatus tendons 
(n = 8 donors). Cells were cultured in DMEM F12 phenol red free medium containing 1% heat inactivated 
human serum to 80% confluence and incubated with IL-1β for 24 h. Media and cells were harvested and placed 
in ice-cold methanol containing deuterium labeled internal standards. LM were then extracted and profiled. (A) 
2-dimensional score plot and (B) corresponding 2-dimensional loading plot of plasma LM-SPM from human 
tendon derived-stromal cell incubations isolated from healthy volunteers or patients with tendinopathy after 
stimulation with IL-1β (10ngml—1) for 24 h. Grey ellipse in the score plot denotes 95% confidence regions. (C) 
Concentrations for mediators found to be differentially regulated between healthy (grey bars) and diseased (black 
bars) tendon stromal cell incubations. Results are shown as means and SEM and representative of n = 8 donors 
per group. (D) mRNA expression of lipid mediator biosynthetic enzymes determines using real time qPCR. Gene 
expression is normalized to β-actin, bars show median values. (E) Representative immunofluorescence images 
showing staining for ALOX15 (green), PTGS2 (red) and nuclei (cyan) in IL-1β-stimulated healthy and diseased 
tendon cells. Scale bar, 20μm. Results are representative of n = 3 donors.
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Incubation of tendon-derived stromal cells with 10 nM MaR1 also significantly up regulated SPM concentrations 
in incubations with healthy cells. Here we found increases in RvD and LX as well as statistically significant decreases 
in inflammation initiating eicosanoids including PGE2 (Fig. 3A and B, Supplemental Fig. 3 and Supplemental 
Table 1). Incubation of diseased tendon cells with MaR1 also lead to a decrease in the levels of PG and Tx, although 
as observed for 15-epi-LXA4 the reduction in these pro-inflammatory eicosanoids was less than that observed 
with cells from healthy volunteers (Fig. 3, Supplemental Fig. 3 and Supplemental Table 2). In addition to regulating 
eicosanoid production, incubation of MaR1 with diseased tendon cells also lead to down-regulation of mRNA and 
protein of PDPN, STAT-1 and IL-6 (Fig. 3C–E). Together these findings demonstrate that MaR1 and 15-epi-LXA4 
counter regulate IL-1β initiated inflammation in tendon-derived stromal cells. They also point to a dysregulated 
resolution response in cells derived from patients with tendinopathy, given the lower potency of these mediators at 
regulating the production of both pro-resolving and pro-inflammatory mediators.
DHA bioactive 
metabolome Q1 Q3
Tendon stromal cells Lipid mediators levels (pg/
incubation)
Healthy + IL-1β Disease + IL-1β
RvD1 375 141 5.3 ± 1.8 4.6 ± 2.0
RvD2 375 141 8.7 ± 4.3 11.6 ± 5.3
RvD3 375 147 4.1 ± 2.5 6.6 ± 2.7
RvD4 375 101 4.2 ± 2.1 7.9 ± 3.3
RvD5 359 199 53.9 ± 11.1 49.3 ± 7.1
RvD6 359 101 24.1 ± 7.7 13.9 ± 2.7
17R-RvD1 375 141 1.9 ± 0.6 2.1 ± 0.6
17R-RvD3 375 147 5.7 ± 1.7 7.6 ± 2.1
PD1 359 153 27.6 ± 5.8 26.6 ± 9.5
17R-PD1 359 153 1.0 ± 0.2 1.7 ± 1.0
10 S,17S-diHDHA 359 153 139.7 ± 10.3 117.1 ± 41.3
MaR1 359 221 6.3 ± 2.4 28.7 ± 11.8*
7 S,14S-diHDHA 359 221 40.5 ± 22.3 7.9 ± 2.9
4 S,14S-diHDHA 359 101 15.8 ± 6.8 19.8 ± 6.9
n-3 DPA bioactive metabolome
RvD1n-3 DPA 377 143 2.0 ± 0.8 4.8 ± 1.0*
RvD2n-3 DPA 377 261 0.7 ± 0.6 2.3 ± 1.3
RvD5n-3 DPA 361 263 19.9 ± 4.3 23.0 ± 5.9
PD1n-3 DPA 361 183 58.0 ± 26.4 98.6 ± 54.0
10 S,17S-diHDPA 361 183 414.3 ± 207.1 499.3 ± 263.5
MaR1n-3 DPA 361 249 13.8 ± 5.6 13.3 ± 4.5
EPA bioactive metabolome
RvE1 349 195 0.3 ± 0.2 0.1 ± 0.1
RvE2 333 199 39.8 ± 10.1 54.3 ± 6.0
RvE3 333 201 2.0 ± 1.1 2.0 ± 0.9
AA bioactive metabolome
LXA4 351 217 2.2 ± 1.0 6.0 ± 1.7*
LXB4 351 221 40.9 ± 18.5 96.2 ± 52.9
5 S,15S-diHETE 335 235 1404.0 ± 358.7 1727.2 ± 437.5
15epi-LXA4 351 217 82.8 ± 48.4 245.2 ± 78.3*
15epi-LXB4 351 221 57.7 ± 16.8 43.6 ± 12.4
15-oxo-LXA4 349 233 0.5 ± 0.2 3.0 ± 1.3*
LTB4 335 195 57.0 ± 49.4 0.0 ± 0.0
5 S,12S-diHETE 335 195 138.8 ± 63.9 264.8 ± 88.0
PGD2 351 189 2065.8 ± 906.4 968.0 ± 294.1
PGE2 351 189 9483.0 ± 4429.1 21371.2 ± 8192.9
PGF2α 353 193 367.0 ± 79.8 380.1 ± 102.5
TxB2 369 169 20.8 ± 5.8 12.1 ± 2.2
Table 1. Altered LM profiles of diseased tendon stromal cells when compared to those from healthy tendon 
stromal cells. Tendon stromal cells (60,000 cells per well) were derived from healthy hamstring (n = 8 donors) 
or diseased supraspinatus tendons (n = 8 donors). Cells were incubated for 24 h with IL-1β, incubations were 
quenched using ice-cold methanol containing deuterium labelled internal standards and lipid mediators (LM) 
were identified and quantified using LM profiling (see methods for details). Q1, M-H (parent ion) and Q3, 
diagnostic ion in the MS-MS (daughter ion). Results are expressed as pg/incubation. Mean ± SEM of n = 8 per 
incubation. *P < 0.05 vs Healthy. The detection limit was ~ 0.1 pg. -, Below levels found in media alone.
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Figure 2. 15-epi-LXA4 up regulates SPM and decreases pro-inflammatory mediators in healthy and diseased 
tendon stromal cells. Tendon stromal cells were derived from healthy hamstring (H, n = 7 donors) or diseased 
supraspinatus tendons (TD, n = 6 donors). Cells were incubated with 15-epi-LXA4 (0.1 or 10 nM) or Vehicle for 
24 h at 37 °C then with IL-1β (10ngml—1) for 24 h. (A,B) LM were identified and quantified using LM profiling 
(see methods for details). Cumulative levels (A) DHA-derived (RvD, PD, MaR) n-3 DPA-derived (RvDn-3 
DPA, PDn-3 DPA, MaR1n-3 DPA), EPA-derived (RvE) and AA-derived (LX) pro-resolving mediator levels. (B) Pro-
inflammatory eicosanoids (PG, Tx) in tendon stromal cells from healthy volunteers (HV) and patients with 
tendinopathy (TD). Statistically significant differences were calculated using pairwise Mann-Whitney U tests. 
*p < 0.05 vs Vehicle incubations. (C) Incubation of IL-1β stimulated diseased tendon cells in 0.1 or 10 nM 
15-epi-LXA4 induced expression of ALOX15 mRNA relative to vehicle controls. (D) Immunocytochemistry 
for ALOX15 in IL-1β stimulated diseased tendon stromal cells incubated in 10 nM 15-epi-LXA4. (E) mRNA 
expression of PDPN, STAT-1 and IL-6 determined using quantitative RTPCR. Gene expression is normalized 
www.nature.com/scientificreports/
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Cells from tendinopathy patients display enhanced ability for further conversion of SPM to 
metabolites that carry reduced biological actions. Having determined that the biological actions of 
15-epi-LXA4 and MaR1 were blunted in tendon cells derived from donors with tendinopathy, we next inves-
tigated the mechanism underpinning this observation. Given that SPM further metabolism may lead to their 
inactivation31, we investigated SPM further metabolism of 15-epi-LXA4 and MaR1 in IL-1β-stimulated tendon 
cells derived from healthy (n = 7) and diseased (n = 6) donors incubated in either 10 nM 15-epi LXA4 or 10 nM 
MaR1. In incubations of diseased or healthy tendon cells with IL-1β and 15-epi-LXA4 (10 nM), we identified the 
inactive LX further metabolite 15-oxo-LXA4 (Fig. 4A). Concentrations of this inactive LX further metabolite were 
elevated in diseased cells compared to healthy cells (p = 0.01) (Fig. 4A, Supplemental Tables 1 and 2). Similarly, in 
incubations with cells from tendinopathy patients, IL-1β and MaR1 (10 nM) we found elevated concentrations of 
the MaR1 metabolite 14-oxo-MaR1 compared to healthy cells incubated with IL-1β and MaR1 (p = 0.01) (Fig. 4B, 
Supplemental Tables 1 and 2).
Diseased tendon cells and tissues show increased PGDH expression. Since tendon stromal cells 
from diseased donors had an enhanced ability to convert 15-epi-LXA4 and MaR1 into metabolites that possess 
reduced biological actions, we investigated the expression of enzymes implicated in SPM metabolism in healthy 
and diseased tendon tissues and cells. NAD + dependent 15-Prostaglandin Dehydrogenase (15-PGDH) is a 
short-chain dehydrogenase/reductase (classified as SDR36C1)32, 33, that converts PGE2 and LXA4 to 15-keto-PGE2 
and 15-oxo-LXA4 respectively34. We therefore investigated expression of 15-PGDH mRNA and protein in cells 
and tissues derived from healthy and diseased human tendons. 15-PGDH mRNA and protein were highly 
expressed in cells isolated from diseased supraspinatus compared to healthy hamstring tendons after IL-1β treat-
ment for 24 h (p = 0.008) (Fig. 4C and D). Tissues derived from patients with supraspinatus tendinopathy (n = 14) 
showed increased 15-PGDH mRNA compared to healthy (subscapularis) shoulder tendons (n = 4) (p = 0.018) 
(Fig. 4E). Expression of 15-PGDH protein was also determined in these healthy and diseased human shoul-
der tendon tissues. Immunostaining confirmed increased 15-PGDH protein in diseased compared to healthy 
shoulder tendons (Fig. 4F). Together these results suggest that the increase in 15-PGDH leads to rapid further 
metabolism and inactivation of the SPM in cells from diseased patients, thereby blunting their biological actions.
15-PGDH inhibition prevents 15-epi-LXA4 and MaR1 further conversion. Having identified 
increased 15-PGDH and enhanced SPM further metabolism in cells from patients with tendinopathy, we inves-
tigated whether 15-PGDH was indeed responsible for inactivation of these mediators in cells derived from these 
patients. For this purpose, we incubated cells with either the 15-PGDH inhibitor SW03329135 or indomethacin 
which in addition to its effects on COX also inhibits 15-PGDH activity36, and is used clinically to moderate 
inflammation37. In incubations of IL-1β stimulated diseased tendon stromal cells with either indomethacin or 
SW033291, we found significantly lower concentrations of 15-oxo-LXA4 and 14-oxo-MaR1 levels, and a cor-
responding increase in the levels of 15-epi-LXA4 and MaR1 (Fig. 5A,B Tables 2,3). These results indicated that 
the elevated 15-PGDH expression was responsible for the blunted actions of these mediators in regulating lipid 
mediator profiles in stromal cells from patients with tendinopathy.
We therefore next questioned whether incubating cells with both an SPM and indomethacin or SW033291 
would have additive actions on regulating markers of inflammation in tendon stromal cells. Assessment of IL-6 
production in these cells demonstrated that whereas there were no additive actions with indomethacin, incuba-
tion of SW033291 together with 15-epi-LXA4 displayed additive actions in down-regulating the concentrations 
of this inflammatory cytokine (Fig. 5C). We also found that co-incubation of 15-epi-LXA4 with indometha-
cin displayed additive actions in regulating PDPN and STAT-1 expression (Fig. 5D) compared to incubation in 
15-epi-LXA4 alone (Fig. 2E and G).
Discussion
Specialized proresolving mediators (SPM) including lipoxins, resolvins, protectins and maresins initiate the 
highly active and coordinated process of resolution38, regulating the duration and magnitude of inflammation 
and promoting restoration of tissue homeostasis after infection and/or injury14, 16, 39. Whilst SPMs are implicated 
in resolving acute inflammation via cells of the innate immune system, these bioactive mediators are also asso-
ciated with chronic inflammatory diseases17, 18. Tissue-resident stromal cells such as fibroblasts are emerging as 
an important cell type implicated in mediating the resolution of inflammation in wound healing, periodontal 
disease, pulmonary inflammation and Rheumatoid Arthritis24, 25, 40, 41. Stromal fibroblasts actively participate in 
inflammatory responses and are implicated in governing the persistence of inflammatory disease through a vari-
ety of mechanisms including stromal fibroblast activation, recruitment and retention of immune cells, inhibition 
of leucocyte apoptosis and immunological memory13.
Chronic inflammation is a common feature of musculoskeletal soft tissue diseases including tendinopathy9. 
Tendons possess a low rate of tissue turnover42, therefore damage accumulated may be long lasting as diseased 
tissue heals by fibrosis and not regeneration. Current therapeutic strategies focus on ameliorating the pain asso-
ciated with disease but do not address the underlying biological mechanisms underpinning the development of 
to β-actin, bars show median values. (F) ELISA assay of IL-6 protein secretion from IL-1β stimulated diseased 
tendon cells incubated in the presence and absence of 10 nM 15-epi-LXA4. Data are shown as means and SEM, 
n = 4 separate donors. (G) Representative immunofluorescence images showing staining for STAT-1 (green), 
IL-6 (red), PDPN (green), and nuclei (cyan) in IL-1β stimulated diseased tendon stromal cells incubated in 
10 nM 15-epi-LXA4. All images are representative of n = 3 donors. Scale bar, 20 μm.
www.nature.com/scientificreports/
7SCieNtifiC RepoRts | 7: 11009  | DOI:10.1038/s41598-017-11188-y
chronic inflammation. Resolution of inflammation has not been well studied in the context of diseased human 
musculoskeletal soft tissues.
In the present study we found that incubation of tendon-derived stromal cells with IL-1β up regulated the 
production of pro-inflammatory eicosanoids and proresolving SPM. Furthermore, the production of select 
Figure 3. MaR1 counter regulates the inflammatory actions of IL-1β in healthy and diseased tendon stromal 
cells. Tendon stromal cells were derived from healthy hamstring (H, n = 7 donors) or diseased supraspinatus 
tendons (TD, n = 6 donors). Cells were incubated with MaR1 (10 nM) or Vehicle for 24 h at 37 °C then with 
IL-1β (10ngml—1) for 24 h. (A,B) LM were identified and quantified using LM profiling (see methods for 
details). Cumulative levels (A) DHA Derived (RvD, PD, MaR) n-3 DPA-derived (RvDn-3 DPA, PDn-3 DPA, 
MaR1n-3 DPA), EPA-derived (RvE) and AA-derived (LX) proresolving mediator levels. (B) Pro-inflammatory 
eicosanoids (PG, Tx) in tendon stromal cells from healthy volunteers (HV) and patients with tendinopathy 
(TD). Statistically significant differences were calculated using pairwise Mann-Whitney U tests. *p < 0.05 vs 
Vehicle incubations. (C) mRNA expression of PDPN, STAT-1 and IL-6 determined using quantitative RTPCR. 
Gene expression is normalized to β-actin, bars show median values. (D) ELISA assay of IL-6 protein secretion 
from IL-1β stimulated diseased tendon cells incubated in the presence and absence of 10 nM MaR1. Data are 
shown as means and SEM, n = 4 separate donors. (E) Representative immunofluorescence images showing 
staining for STAT-1 (green), IL-6 (red), PDPN (green), and nuclei (cyan) in IL-1β stimulated diseased tendon 
stromal cells incubated in 10 nM MaR1. All images are representative of n = 3 donors. Scale bar, 20 μm.
www.nature.com/scientificreports/
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Figure 4. Enhanced further metabolism of 15-epi-LXA4 and MaR1 in diseased tendon stromal cells. Cells 
were incubated with 10 nM of 15-epi-LXA4, MaR1 or vehicle for 24 h at 37 °C then with IL-1β for 24 h at 37 °C. 
At the end of the incubations 2 volumes of ice-cold methanol were added and products were identified and 
quantified using LM profiling (see methods for details). (A) MS-MS spectrum employed for the identification of 
15-oxo-LXA4 (left panel); and 15-oxo-LXA4 concentration in stromal cell incubations from healthy volunteers 
(HV) and patients with tendinopathy (TD; right panel) (B) MS-MS Spectrum employed for the identification 
of 14-oxo-MaR1 (left panel); and 14-oxo-MaR1 concentration in stromal cell incubations from HV and 
TD (right panel). Statistically significant differences were calculated using pairwise Mann-Whitney U tests. 
Results are presented as means ± SEM. *P ≤ 0.05, n = 7 donors for HV and 6 donors for TD. (C) 15-PGDH 
mRNA expression in stromal cells derived from healthy hamstring (n = 5) and diseased supraspinatus tendons 
(n = 5) after stimulation with IL-1β (10ngml—1) for 24 h. Statistically significant differences were calculated 
using pairwise Mann-Whitney U tests. Gene expression is normalized to β-actin, bars show median values. 
www.nature.com/scientificreports/
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pro-resolving mediators was significantly higher in tendon stromal cells from patients with tendinopathy com-
pared with those from healthy volunteers. These results are in line with an increased SPM biosynthetic enzyme 
observed in these cells, pointing to a status of dysregulated resolution, where in response to an inflammatory 
stimulus, in this case IL-1β, the up regulation of tissue protective mediators is not sufficient to counter regulate 
the inflammatory profile. Of note, addition of either 15-epi-LXA4 or MaR1 to the cell incubations also led to a 
feed forward production in endogenous SPM production by both healthy volunteer and diseased tendon stro-
mal cells. These findings are also in line with an increased expression of the SPM biosynthetic enzyme ALOX15 
observed in these cells as well as with published findings in other experimental systems including peritonitis43 
and asthma44, where the administration of one SPM triggers the formation of different SPM that contribute to 
the resolution of inflammation. These findings suggest that diseased tendon cells display a pro-inflammatory and 
dysregulated resolution profile as summarized in Figure S4. Our findings are consistent with earlier reports that 
demonstrate pro-inflammatory mediators including IL-1β induce the production of PGE2 in cultures of tendon 
cells45, 46.
Having observed that a select group of pro-resolving mediators was up regulated in patient-derived com-
pared to healthy tendon stromal cells, we queried whether these autacoids carried biological actions in regulating 
molecular aspects of tendon inflammation. Indeed 15-epi-LXA4 and MaR1 regulated lipid mediator production 
in both healthy and patient tendon-derived stromal cells. In addition, incubation of patient derived tendon cells 
with these SPM also led to a reduction of IL-6, STAT-1 and PDPN, that we have previously found to be associ-
ated with disease severity9, 11. Of note, we found that the biological actions of both 15-epi-LXA4 and MaR1 were 
blunted in patient-derived tendon cells, this decreased effectiveness was associated with an increased further 
metabolism of these mediators to their inactive metabolites. This process of inactivation was at least in part reli-
ant on 15-PGDH since this enzyme was found to be up regulated in patient cells compared with tendon stromal 
cells from healthy volunteers. Furthermore, inhibition of this enzyme using either indomethacin or SW033291 
led to increased recovery of both 15-epi-LXA4 and MaR1 and a reduction in the further metabolism of these 
mediators in diseased tendon stromal cell incubations. 15-PGDH has been recently shown to negatively regulate 
tissue repair and regeneration in murine models of bone marrow, colon and liver injury35. Zhang et al., illus-
trated that 15-PGDH blockade potentiated repair in multiple murine tissues without apparent adverse effects. 
Having found that the 15-PGDH inhibitors reduced both SPM further metabolism and prostaglandin produc-
tion, we also queried whether co-incubation of either 15-epi-LXA4 or MaR1 with these inhibitors moderated the 
pro-inflammatory phenotype of diseased tendon stromal cells. In these incubations we found a further reduction 
in the expression of IL-6, STAT-1 and PDPN as well as prostaglandins, although this was not statistically signif-
icant. Future experiments will need to investigate the potential of this approach and the possibility of obtaining 
additive or even synergistic actions with a dual pronged approach in controlling soft tissue inflammation, in line 
with actions observed in bacterial infections where SPMs lower the required doses of antibiotics required to clear 
infections47.
We acknowledge there are potential limitations with the use of hamstring tendon as a comparator to dis-
eased tendons including tendon type and donor age differences. However, hamstring tendon was taken from live 
healthy donors without history of tendinopathy. We believe this is a more suitable comparator than cadaveric 
shoulder tendon tissues where little is known about whether the tendons were healthy or diseased and tendons 
were not affected by post mortem changes.
The findings from this study suggest that tendinopathy is characterized by a status of dysregulated resolu-
tion that results from an up regulation of 15-PGDH leading to the rapid inactivation of SPM. Incubation of 
tendon-derived stromal cells from both healthy volunteers and patients with tendinopathy in SPM including 
15-epi-LXA4 or MaR1 induced further release of proresolving mediators and counter regulated the expression 
of pro-inflammatory molecules including PGE2, IL-6, STAT-1 and PDPN. In addition, our findings suggest that 
a dual pronged approach, using pro-resolving mediators together with inhibitors to 15-PGDH may represent a 
novel therapeutic strategy to reduce local inflammation and promote tissue repair and regeneration.
Materials and Methods
Study Approval. Healthy and diseased tendon tissues were collected under research ethics from the Oxford 
Musculoskeletal Biobank (09/H0606/11). Full informed consent according to the Declaration of Helsinki was 
obtained from all patients. Experimental protocols were performed at the University of Oxford in accordance 
with research ethics from the Oxford Musculoskeletal Biobank (09/H0606/11).
Collection of human tendon tissues. All patients were recruited from orthopedic referral clinics where 
the structural integrity of the supraspinatus tendon was determined ultrasonographically. Patients presenting to 
the referral shoulder clinic had failed non-operative treatment, including a course of physical therapy, and had 
experienced pain for a minimum of 3 months. Patients completed the Oxford Shoulder Score (OSS), a validated 
and widely used clinical outcome measure scoring from 0 (severe pathology) to 48 (normal function). Diseased 
(D) Representative immunofluorescence images of tendon stromal cells isolated from healthy hamstring 
donors (n = 3) and patients (n = 3) with supraspinatus tendinopathy showing staining for 15-PGDH (red) and 
nuclei (cyan) after stimulation with IL-1β (10ngml—1) for 24 h. (E) 15-PGDH mRNA expression in healthy 
subscapularis (n = 4 donors) and diseased supraspinatus (n = 14 donors) shoulder tendon tissues. Gene 
expression is normalized to β-actin, bars show median values. (F) Representative immunofluorescence images 
of sections of diseased and healthy shoulder tendons stained for 15-PGDH (red). Cyan represents POPO-1 
nuclear counterstain. Scale bars, 20μm.
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Figure 5. 15-PGDH inhibition attenuates the conversion of SPMs to biologically inactive metabolites and 
regulates markers of inflammation in diseased tendon stromal cells. (A,B) Diseased tendon stromal cells isolated 
from patients with supraspinatus tendinopathy were pre-incubated with 10μM indomethacin (Indo) or 25 μM 15-
PGDH inhibitor (SW033291) for 2 h, followed by incubation in 10 nM of 15-epi-LXA4 or MaR1 or vehicle for 24 h 
at 37 °C. Incubations were then treated with IL-1β for 24 h at 37 °C. Lipid mediators were identified and quantified 
using lipid mediator profiling. (A) 15-oxo-LXA4 and 14-oxo-MaR1 concentrations; (B) 15-epi-LXA4 and MaR1 
concentrations relative to amounts added to each incubation. Statistically significant differences were calculated 
using one-way ANOVA followed by Tukey post hoc test. Data are shown as means and SEM, n = 3 separate donors. 
*p < 0.05 vs cells + IL-1β. (C) ELISA assay of IL-6 protein secretion from IL-1β stimulated diseased tendon cells 
in the presence of 15-PGDH inhibitors and 15-epi-LXA4 or MaR1. Data are shown as means and SEM, n = 4 
separate donors. **P < 0.01. (D) Representative immunofluorescence images showing staining for PDPN (green), 
STAT-1 (green), IL-6 (red) and nuclei (cyan) in IL-1β-stimulated diseased tendon stromal cells incubated in 10 μM 
indomethacin and 10 nM 15-epi-LXA4 or vehicle control media (n = 3 separate donors). Scale bar, 20 μm.
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tendon tissues (supraspinatus tendon tears) were collected at the time of surgical debridement of the edges of the 
torn tendons from 28 male and female patients aged between 44 and 75 (mean 55 ± 18.3 years). All patients were 
symptomatic and had small to medium tears (≤1 cm to ≤3 cm in anterior-posterior length). Exclusion criteria 
for all patients in this study included previous shoulder surgery, other shoulder pathology, rheumatoid arthritis 
and systemic inflammatory disease. Samples of healthy supraspinatus (n = 5) and subscapularis tendons (n = 4) 
were collected intra-operatively from male and female patients between 25–65 years of age that were undergoing 
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1β + MaR1 + SW033291
RvD1 375 141 0.2 ± 0.2 0.0 ± 0.0 — — — —
RvD2 375 141 0.6 ± 0.4 0.9 ± 0.3 — — 0.1 ± 0.1 0.2 ± 0.2
RvD3 375 147 0.3 ± 0.3 0.4 ± 0.4 — — — —
RvD4 375 101 1.3 ± 1.3 0.5 ± 0.3 — — — —
RvD5 359 199 34.0 ± 3.8 32.9 ± 7.1 1.3 ± 1.3** 0.3 ± 0.3** 8.6 ± 1.2** 7.1 ± 1.6
RvD6 359 101 14.9 ± 2.5 13.5 ± 2.3 4.1 ± 0.5** 7.4 ± 1.1** 3.1 ± 1.3** 2.0 ± 0.4
17R-RvD1 375 141 1.2 ± 0.7 0.6 ± 0.2 — 0.2 ± 0.2 — 0.1 ± 0.1
17R-RvD3 375 147 2.5 ± 1.5 2.4 ± 0.9 — * — — 0.0 ± 0.0
PD1 359 153 7.0 ± 1.1 3.5 ± 0.8* 1.5 ± 1.0 * 0.1 ± 0.1 1.4 ± 0.7** 0.2 ± 0.2
17R-PD1 359 153 0.2 ± 0.1 0.2 ± 0.2 — 0.0 ± 0.0 0.1 ± 0.1 0.6 ± 0.3
10 S,17S-diHDHA 359 153 34.6 ± 5.2 46.8 ± 4.7 0.6 ± 0.6* 1.7 ± 1.7 0.9 ± 0.9 ** 0.8 ± 0.8
MaR1 359 221 0.9 ± 0.9 560.3 ± 64.4 ** 0.0 ± 0.0 723.4 ± 42.5**$ 0.7 ± 0.7 662.3 ± 59.5 **##
MaR2 359 191 0.5 ± 0.3 — 0.7 ± 0.3 1.9 ± 0.2*$ 2.1 ± 0.5* — #
7 S,14S-diHDHA 359 221 32.0 ± 5.2 34.9 ± 1.4 — 28.8 ± 1.9$ —** —
4 S,14S-diHDHA 359 101 — — — — — —
14-oxo-MaR1 357 248 0.3 ± 0.2 18.1 ± 2.9 ** 0.3 ± 0.2 11.0 ± 0.9 ** $ 0.2 ± 0.2 7.6 ± 0.8 **#
n-3 DPA bioactive metabolome
RvD1n-3 DPA 377 143 3.2 ± 1.9 3.4 ± 0.8 0.1 ± 0.1 1.2 ± 0.6 — 0.5 ± 0.5
RvD2n-3 DPA 377 261 0.4 ± 0.3 0.3 ± 0.3 — 0.0 ± 0.0 — —
RvD5n-3 DPA 361 263 25.4 ± 1.7 13.4 ± 2.5 — ** 0.7 ± 0.7 ** — ** — **
PD1n-3 DPA 361 183 0.9 ± 0.5 1.3 ± 0.3 0.4 ± 0.4 1.5 ± 0.1 4.2 ± 1.8 0.7 ± 0.4
10 S,17S-diHDPA 361 183 16.8 ± 1.7 16.7 ± 2.3 5.2 ± 1.3 * 5.1 ± 1.3 3.3 ± 0.5 ** 3.5 ± 0.7 **
MaR1n-3 DPA 361 249 3.9 ± 2.1 0.5 ± 0.2 0.4 ± 0.4 1.5 ± 1.5 0.1 ± 0.1 0.1 ± 0.1
EPA bioactive metabolome
RvE1 349 195 — — — 0.2 ± 0.0 $ —** 0.2 ± 0.1
RvE2 333 199 49.0 ± 11.7 31.8 ± 2.4 18.9 ± 2.0 * 15.8 ± 3.5 23.6 ± 4.0 * 12.5 ± 1.4 *#
RvE3 333 201 0.4 ± 0.3 0.5 ± 0.3 — — — —
AA bioactive metabolome
LXA4 351 217 — — — — — —
LXB4 351 221 1.4 ± 1.4 17.2 ± 17.2 — 3.1 ± 3.1 — —
5 S,15S-diHETE 335 235 121.8 ± 14.8 750.1 ± 203.5* —* —* —** —**
15epi-LXA4 351 217 — — — — — —
15epi-LXB4 351 221 35.0 ± 7.3 69.8 ± 12.1* 18.5 ± 3.6* 33.8 ± 5.3$ —** —**
15-oxo-LXA4 349 233 — 0.1 ± 0.1 — — 0.1 ± 0.0 0.1 ± 0.1
LTB4 335 195 — — —
5 S,12S-diHETE 335 195 45.6 ± 45.6 36.4 ± 18.3 — — —
PGD2 351 189 50.0 ± 4.0 34.0 ± 9.5 0.7 ± 0.7** 0.7 ± 0.7** 1.2 ± 1.2** 1.0 ± 1.0**
PGE2 351 189 1655.4 ± 108.7 1275.0 ± 95.0 * 4.6 ± 3.6** 8.9 ± 1.9** 154.5 ± 14.8** 103.0 ± 14.4**#
PGF2α 353 193 258.1 ± 26.0 400.7 ± 138.5 —** ** 2.4 ± 2.2** 3.3 ± 1.9**
TxB2 369 169 374.8 ± 31.5 554.3 ± 191.6 —** —** 3.3 ± 3.0** 8.3 ± 0.6**
Table 2. SPM profiles in IL-1β stimulated diseased tendon stromal cells incubated in MaR1 and inhibitors of 
15-PGDH. Tendon stromal cells (60,000 cells per well) were derived from diseased supraspinatus tendons. Cells 
were incubated for 24 h (37 °C) with indomethacin (indo; 10 µM), SW033291 (25 µM) or vehicle (2 h, 37 °C), 
then with MaR1 (10 nM) or vehicle (24 h 37 °C) and with IL-1β (37 °C; 24 h). Incubations were quenched using 
ice-cold methanol containing deuterium labelled internal standards and lipid mediators (LM) were identified 
and quantified using LM-profiling (see methods for details). Q1, M-H (parent ion) and Q3, diagnostic ion in the 
MS-MS (daughter ion). Results are expressed as pg/incubation. Mean ± SEM of n = 3 per incubation. *P < 0.05, 
**P < 0.01 vs Disease + IL1β incubations. $P < 0.05, $$P < 0.01 vs Disease + IL1β  + Indo; #P < 0.05, ##P < 0.01 vs 
Disease + IL1β  + SW. The detection limit was ~0.1 pg. -, Below levels found in media alone.
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shoulder surgery for post-traumatic instability. Healthy hamstring tendons were collected from 15 male and 
female patients undergoing surgical reconstruction of their anterior cruciate ligament. All patients were aged 
between 18 and 48 (mean 25.2 ± 11 years).
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Disease + IL-1β + 15-epi-
LXA4 + SW033291
RvD1 375 141 0.2 ± 0.2 1.0 ± 1.0 — — — —
RvD2 375 141 0.6 ± 0.4 1.3 ± 0.3 — — 0.1 ± 0.1 —
RvD3 375 147 0.3 ± 0.3 0.2 ± 0.1 — — — —
RvD4 375 101 1.3 ± 1.3 1.9 ± 0.2 — — — —
RvD5 359 199 34.0 ± 3.8 27.5 ± 5.2 1.3 ± 1.3** 0.3 ± 0.3** 8.6 ± 1.2** 2.1 ± 1.2**
RvD6 359 101 14.9 ± 2.5 20.4 ± 0.4* 4.1 ± 0.5** 4.1 ± 0.2** 3.1 ± 1.3** 1.0 ± 0.7**
17R-RvD1 375 141 1.2 ± 0.7 2.4 ± 1.3 — 0.3 ± 0.3 — —
17R-RvD3 375 147 2.5 ± 1.5 4.5 ± 1.1 — * — — —
PD1 359 153 7.0 ± 1.1 7.0 ± 1.0 1.5 ± 1.0* 0.8 ± 0.7** 1.4 ± 0.7** 0.7 ± 0.7**
17R-PD1 359 153 0.2 ± 0.1 0.3 ± 0.3 — 0.0 ± 0.0 0.1 ± 0.1 0.3 ± 0.2
10 S,17S-diHDHA 359 153 34.6 ± 5.2 64.3 ± 6.2* 0.6 ± 0.6* 1.8 ± 1.8** 0.9 ± 0.9** —**
MaR1 359 221 0.9 ± 0.9 13.2 ± 2.1** 0.0 ± 0.0 1.2 ± 1.2 0.7 ± 0.7 —
MaR2 359 191 0.5 ± 0.3 1.0 ± 0.1 0.7 ± 0.3 1.0 ± 0.6 2.1 ± 0.5* —
7 S,14S-diHDHA 359 221 32.0 ± 5.2 22.1 ± 6.7 — 0.4 ± 0.4** —** —**
4 S,14S-diHDHA 359 101 — — — — — —
14-oxo-MaR1 357 248 0.3 ± 0.2 0.4 ± 0.4 0.3 ± 0.2 0.1 ± 0.1 0.2 ± 0.2 —
n-3 DPA bioactive metabolome
RvD1n-3 DPA 377 143 3.2 ± 1.9 4.7 ± 0.6 0.1 ± 0.1 0.2 ± 0.2 — —
RvD2n-3 DPA 377 261 0.4 ± 0.3 — — 0.0 ± 0.0 — —
RvD5n-3 DPA 361 263 25.4 ± 1.7 14.6 ± 2.4 * — ** 1.2 ± 1.2 — ** — **
PD1n-3 DPA 361 183 0.9 ± 0.5 2.2 ± 1.1 0.4 ± 0.4 0.8 ± 0.2 4.2 ± 1.8 0.9 ± 0.3
10 S,17S-diHDPA 361 183 16.8 ± 1.7 16.8 ± 2.3 5.2 ± 1.3 * 6.0 ± 0.7 ** 3.3 ± 0.5 ** 3.3 ± 1.0 **
MaR1n-3 DPA 361 249 3.9 ± 2.1 2.8 ± 0.6 0.4 ± 0.4 0.4 ± 0.2 0.1 ± 0.1 —
EPA bioactive metabolome
RvE1 349 195 — — — 0.0 ± 0.0 — ** 0.1 ± 0.1
RvE2 333 199 49.0 ± 11.7 44.3 ± 9.4 18.9 ± 2.0 * 22.3 ± 4.6 * 23.6 ± 4.0 * 24.6 ± 4.0
RvE3 333 201 0.4 ± 0.3 0.0 ± 0.0 — 0.0 ± 0.0 — —
AA bioactive metabolome
LXA4 351 217 — 15.9 ± 10.6 — 4.9 ± 0.5** $ — 2.4 ± 1.4
LXB4 351 221 1.4 ± 1.4 — — 0.0 ± 0.0 — —
5 S,15S-diHETE 335 235 121.8 ± 14.8 770.0 ± 168.4** — * 2.9 ± 2.9* — ** —
15epi-LXA4 351 217 — 253.2 ± 16.3** — 291 ± 20.2**$$ — 297.1 ± 23.9**##
15epi-LXB4 351 221 35.0 ± 7.3 45.5 ± 6.6 18.5 ± 3.6* 21.3 ± 5.9 — ** 5.4 ± 2.7*
15-oxo-LXA4 349 233 — 3.0 ± 0.5* — 0.6 ± 0.1$$ 0.1 ± 0.0 0.5 ± 0.2* #
LTB4 335 195 — —
5 S,12S-diHETE 335 195 45.6 ± 45.6 40.9 ± 31.1 — 0.0 ± 0.0 — —
PGD2 351 189 50.0 ± 4.0 61.0 ± 9.4 0.7 ± 0.7** 30.8 ± 3.8* # 1.2 ± 1.2 ** 29.4 ± 6.0*#
PGE2 351 189 1655.4 ± 108.7 1275.0 ± 95.0 ** 4.6 ± 3.6** 4.8 ± 3.8** 154.5 ± 14.8** 74.6 ± 20.7** #
PGF2α 353 193 258.1 ± 26.0 258.8 ± 51.3 —** 0.0 ± 0.0** 2.4 ± 2.2** 5.7 ± 5.3**
TxB2 369 169 374.8 ± 31.5 367.9 ± 77.2 — ** 0.0 ± 0.0** 3.3 ± 3.0** 7.9 ± 7.4**
Table 3. SPM profiles in IL-1β stimulated diseased tendon stromal cells incubated in 15-epi-LXA4 and 
inhibitors of 15-PGDH. Tendon stromal cells (60,000 cells per well) were derived from diseased supraspinatus 
tendons. Cells were incubated for 24 h (37 °C) with indomethacin (indo; 10 µM), SW033291 (25 µM) or vehicle 
(2 h, 37 °C), then with 15-epi-LXA4 (10 nM) or vehicle (24 h 37 °C) and with IL-1β (37 °C; 24 h). Incubations 
were quenched using ice-cold methanol containing deuterium labelled internal standards and lipid mediators 
(LM) were identified and quantified using LM-profiling (see methods for details). Q1, M-H (parent ion) 
and Q3, diagnostic ion in the MS-MS (daughter ion). Results are expressed as pg/incubation. Mean ± SEM 
of n = 3 per incubation. *P < 0.05, **P < 0.01 vs Disease + IL1β incubations. $P < 0.05, $$P < 0.01 vs 
Disease + IL1β  + Indo; #P < 0.05, ##P < 0.01 vs Disease + IL1β  + SW. The detection limit was ~ 0.1 pg. -, Below 
levels found in media alone.
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Isolation of tendon-derived stromal cells from healthy and diseased tendons. Fresh samples 
of healthy hamstring or diseased supraspinatus tendons were cut into 2mm3 explants and incubated in DMEM 
F12 media (Lonza) containing 50% fetal calf serum (FCS, Labtech) and 1% Penicillin Streptomycin (Pen-Strep, 
Lonza). Media were replaced every 4 days and cells allowed to grow out from explants over time in a tissue culture 
incubator at 37 °C and 5% CO2. Once cells were 90% confluent, explants were removed and media replaced with 
DMEM F12 containing 10% FCS and 1% Pen-Strep. Healthy and diseased tendon cells between passages 1–3 were 
used for all experiments. Our previous characterization of human tendon derived stromal cells demonstrated 
cells used for in vitro experiments were CD45neg and CD34neg. Diseased tendon cells are known to highly express 
markers of stromal fibroblast activation including PDPN, CD106 and CD248 compared to healthy tendon derived 
cells11.
Treatment of tendon-derived stromal cells with IL-1β for bioactive lipid mediator profiling. As 
IL-1β induces NF-κB target genes known to be highly expressed in early stage tendinopathy9, we investigated bio-
active pro-resolving lipid mediator profiles in cells derived from healthy and diseased human tendons in the pres-
ence of IL-1β. Tendon-derived stromal cells from healthy hamstring (n = 8) and diseased supraspinatus tendons 
(n = 8) were seeded at a density of 60,000 cells per well in a 6 well plate. Tendon cells were allowed to reach 80% 
confluence prior to stimulation with IL-1β (Merck, 10ngml—1) in DMEM F12 phenol red free medium (Gibco) 
containing 1% heat inactivated human serum (Sigma) and 1% penicillin-streptomycin. Non-treated cells (vehicle 
only, containing 0.1% endotoxin free BSA, Sigma) served as controls for each experiment. After treatment, cells 
were then incubated at 37 °C and 5% CO2 until harvest of the media and lysate for bioactive lipid mediator pro-
filing after 24 h.
Modulating bioactive lipid mediator profiles with 15-epi-LXA4 or MaR1 in IL-1β stimulated 
tendon-derived stromal cells. Tendon stromal cells were derived from healthy hamstring (n = 7) and 
diseased supraspinatus tendons (n = 6). Cells were seeded at a density of 60,000 cells per well. Once cells were 
at 80% confluence, they were pre-incubated with 0.1 nM or 10 nM 15-epi-LXA4 (Cayman Chemical) or 10 nM 
MaR1 (Cayman Chemical) for 24 h in DMEM F12 phenol red free medium (Gibco) containing 1% heat inac-
tivated human serum (Sigma) and 1% penicillin-streptomycin. Cells were subsequently stimulated with IL-1β 
(10ngml—1) as described above in the presence of media containing either 0.1 nM or 10 nM 15-epi-LXA4, 10 nM 
MaR1 or vehicle only control media. After IL-1β treatment, cells were shielded from light and incubated at 37°C 
and 5% CO2 until harvest of the media and lysate for bioactive lipid mediator profiling after 24 h. Parallel experi-
ments were conducted and cell lysates harvested to investigate if incubating cells in 15-epi-LXA4 or MaR1 mod-
ulated expression of pro-inflammatory genes expressed by diseased tendon stromal cells. The concentration and 
integrity of mediators used for these incubations were validated using UV-spectrophotometry and LC-MS-MS in 
accordance with published criteria25.
Bioactive lipid mediator profiling of IL-1β stimulated healthy and diseased tendon stromal 
cells. Media and lysate samples were stored at −80 °C prior to analysis. 2 volumes of ice cold MeOH con-
taining deuterated internal standards (d4-LTB4, d8-5S-HETE, d4-PGE2, d5-LXA4 and d5-RvD2, 500 pg each) were 
added to the samples. These were then kept at −20 °C for 45 minutes to allow for protein precipitation and sub-
jected to solid phase extraction as per previous publication26. Methyl formate fractions were then brought to dry-
ness using a TurboVap LP (Biotage) and products suspended in water-methanol (50:50 vol:vol) for LC-MS-MS. 
A Shimadzu LC-20AD HPLC and a Shimadzu SIL-20AC autoinjector (Shimadzu, Kyoto, Japan), paired with a 
QTrap 5500 (ABSciex, Warrington, UK) were utilised and operated as described26. To monitor each lipid medi-
ator and respective pathways, a Multiple Reaction Monitoring (MRM) method was developed with diagnostic 
ion fragments and identification using recently published criteria26, including matching retention time (RT) to 
synthetic and authentic materials and at least six diagnostic ions for each lipid mediator. Calibration curves were 
obtained for each using authentic compound mixtures and deuterium labeled lipid mediator at 0.78, 1.56, 3.12, 
6.25, 12.5, 25, 50, 100, and 200 pg. Linear calibration curves were obtained for each lipid mediator, which gave r2 
values of 0.98–0.99.
15-PGDH mRNA expression in healthy and diseased tendon tissues and cells. Tendon-derived 
stromal cells from healthy hamstring (n = 5) and diseased supraspinatus tendons (n = 5) were seeded at a den-
sity of 15,000 cells per well in a 24 well plate. Tendon cells were allowed to reach 80% confluence prior to stim-
ulation with IL-1β (Merck, 10ngml—1) in DMEM F12 phenol red free medium (Gibco) containing 1% heat 
inactivated human serum (Sigma) and 1% penicillin-streptomycin. Non-treated cells (vehicle only, containing 
0.1% endotoxin free BSA, Sigma) served as controls for each experiment. After cytokine treatment, cells were 
then incubated at 37 °C and 5% CO2 until harvest of the cell lysate for mRNA after 24 h. For tissues, samples of 
healthy subscapularis (n = 4) and diseased supraspinatus tendons (n = 14) were snap frozen and stored at −80 °C. 
RNA isolation, cDNA synthesis and quantitative PCR were performed using previously published protocols9. 
Pre-validated Qiagen primer assays (15-PGDH, STAT-1, IL6, PDPN, β-actin and GAPDH) were used for qPCR. 
Results were calculated using the ddCt method using reference genes for human β-actin and GAPDH. Results 
were consistent using these reference genes and data are shown normalized to β-actin.
Immunofluorescence for 15-PGDH in healthy and diseased tendons. Tendon samples were 
immersed in 10% buffered formalin, processed using a Leica ASP300S tissue processor and embedded in paraffin 
wax. Tissues were sectioned to 4μm onto adhesive glass slides. For antigen retrieval, slides were baked at 60 °C 
for 60 minutes and tissue sections were taken through deparaffinisation and target retrieval steps (high pH heat 
mediated antigen retrieval) using an automated PT Link (Dako). Immunofluorescence staining protocols and 
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image acquisition are adapted from a previously published protocol9. Sections were incubated with the primary 
antibody anti-15-PGDH (Abcam, ab118185). For negative controls the primary antibody was substituted for uni-
versal isotype control antibodies: cocktail of mouse IgG1, IgG2a, IgG2b, IgG3 and IgM (Dako) (Figure S5).
Immunocytochemistry for healthy and diseased tendon stromal cells. Tendon stromal cells were 
grown in chamber slides and treated as above. Cells were fixed in ice cold methanol for 5 mins and washed twice 
in PBS. Immunofluorescence staining protocols and image acquisition are adapted from a previously published 
protocol9. Tendon stromal cells isolated from 3 healthy hamstring donors and 3 patients with supraspinatus 
tendinopathy were incubated with the following primary antibodies: anti-ALOX15 (Abcam ab119774), anti-
15-PGDH (Abcam, ab118185), anti-STAT-1 (Abcam ab29045), anti-COX2 (Abcam ab15191), anti-Podoplanin 
(Abcam ab10288) and anti-IL-6 (Abcam 9324) in PBS containing 5% goat serum in Saponin for 3 hrs at room 
temperature. For negative controls the primary antibody was substituted for universal isotype control antibodies: 
cocktail of mouse IgG1, IgG2a, IgG2b, IgG3 and IgM (Dako) and rabbit immunoglobulin fraction of serum from 
non-immunized rabbits, solid phase absorbed. Isotype control staining is shown in Figure S5.
Immunofluorescence imaging. Immunofluorescence images were acquired on a Zeiss LSM 710 confocal 
microscope using a × 40 oil immersion objective (NA = 1.3). The fluorophores of POPO-1, Alexa Fluor 488, 
Alexa Fluor 568, and Alexa Fluor 633 were excited using the 405 nm, 488 nm, 561 nm, and 633 nm laser lines 
respectively. To minimize bleed-through, all channels were acquired sequentially. Averaging was set to 2 and the 
pinhole was set to approximately 1 Airy unit. Two-dimensional image reconstructions were created using ZEN 
2009 (Zeiss).
Treatment of diseased tendon stromal cells with inhibitors of 15-PGDH. Tendon stromal cells 
were derived from diseased supraspinatus tendons. Cells were seeded at a density of 60,000 cells per well in 6 
well plates for SPM profiles, (6 donors). Once cells were at 80% confluence, they were pre-incubated in 10μM 
indomethacin (Sigma) or 25μM 15-PGDH inhibitor (SW033291, Tocris) in DMEM F12 phenol red free medium 
containing 1% heat inactivated human serum and 1% penicillin-streptomycin. After 2 h, 10 nM 15-epi Lipoxin 
A4 (Cayman Chemical) or 10 nM Maresin 1 (Cayman Chemical) were added and cells further incubated for 24 h. 
Healthy and diseased cells were then stimulated with IL-1β (10ngml—1), non-treated (vehicle only) IL-1β stimu-
lated cells served as controls for each experiment. Cells were shielded from light and incubated at 37 °C and 5% 
CO2 until harvest of the media and lysate for bioactive lipid mediator profiling 24 h after stimulation with IL-1β.
Quantification of Interleukin-6 in tissue culture media from diseased tendon stromal 
cells. IL-6 is an important cytokine implicated in tissue inflammation. IL-6 in tissue culture supernatants was 
measured using enzyme-linked immunosorbent assay (ELISA) reagents (BD Biosciences). Minimum detectable 
IL-6 concentration for this assay was 2.2 pgml—1. Optical density was read on a spectrophotometric ELISA plate 
reader (FLUOstar Omega, BMG Labtech) and analysed using MARS data analysis software.
Statistics. Statistical analyses were performed using GraphPad Prism 7 (GraphPad Software). Normality was 
tested using the Shapiro-Wilk normality test. Pairwise Mann Whitney U tests were used to test for differences 
between mRNA expression of ALOX12, ALOX15, PTGS2, IL6, STAT-1, PDPN and 15-PGDH in IL-1β treated 
tendon stromal cells in the presence or absence of SPM and inhibitors of 15-PGDH. Pairwise Mann Whitney U 
tests were used to test for differences between IL-6 protein secretion in IL-1β treated tendon stromal cells in the 
presence or absence of SPM and inhibitors of 15-PGDH. Pairwise Mann Whitney U tests were used to test for 
differences between 15-PGDH mRNA expression in healthy and diseased tendon tissues and cells. Analysis of 
bioactive lipid mediator profiles from healthy and diseased tendon cells was performed using multivariate statis-
tical analysis, orthogonal-partial least squares-discriminant analysis (o-PLS-DA) was performed using SIMCA 
14.1 software (Umetrics, Umea, Sweden) following unit variance scaling of LM amounts. PLS-DA is based on a 
linear multivariate model that identifies variables that contribute to class separation of observations (cell incu-
bations) on the basis of their variables (LM levels). During LM classification, observations were projected onto 
their respective class model. The score plot illustrates the systematic clusters among the observations (closer plots 
presenting higher similarity in the data matrix). Loading plot interpretation identified the variables with the best 
discriminatory power (Variable Importance in Projection greater then 1) that were associated with tight clusters 
for lipid mediator profiles obtained from incubations with cells from healthy volunteers or patients with tendin-
opathy. Data are shown as mean and SEM, where n is the biological replicate (human donor of cells derived from 
healthy or diseased tendons). P < 0.05 was considered statistically significant.
Data Availability. All data generated from this study are included in this published article and its 
Supplementary Information files.
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